Erythropoietin improves motor and cognitive deficit, axonal pathology, and neuroinflammation in a combined model of diffuse traumatic brain injury and hypoxia, in association with upregulation of the erythropoietin receptor by unknown
RESEARCH Open Access
Erythropoietin improves motor and cognitive
deficit, axonal pathology, and neuroinflammation
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injury and hypoxia, in association with
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Abstract
Background: Diffuse axonal injury is a common consequence of traumatic brain injury (TBI) and often co-occurs
with hypoxia, resulting in poor neurological outcome for which there is no current therapy. Here, we investigate
the ability of the multifunctional compound erythropoietin (EPO) to provide neuroprotection when administered to
rats after diffuse TBI alone or with post-traumatic hypoxia.
Methods: Sprague–Dawley rats were subjected to diffuse traumatic axonal injury (TAI) followed by 30 minutes of
hypoxic (Hx, 12% O2) or normoxic ventilation, and were administered recombinant human EPO-α (5000 IU/kg) or
saline at 1 and 24 hours post-injury. The parameters examined included: 1) behavioural and cognitive deficit using
the Rotarod, open field and novel object recognition tests; 2) axonal pathology (NF-200); 3) callosal degradation
(hematoxylin and eosin stain); 3) dendritic loss (MAP2); 4) expression and localisation of the EPO receptor (EpoR); 5)
activation/infiltration of microglia/macrophages (CD68) and production of IL-1β.
Results: EPO significantly improved sensorimotor and cognitive recovery when administered to TAI rats with
hypoxia (TAI + Hx). A single dose of EPO at 1 hour reduced axonal damage in the white matter of TAI + Hx rats at
1 day by 60% compared to vehicle. MAP2 was decreased in the lateral septal nucleus of TAI + Hx rats; however, EPO
prevented this loss, and maintained MAP2 density over time. EPO administration elicited an early enhanced
expression of EpoR 1 day after TAI + Hx compared with a 7-day peak in vehicle controls. Furthermore, EPO reduced
IL-1β to sham levels 2 hours after TAI + Hx, concomitant to a decrease in CD68 positive cells at 7 and 14 days.
Conclusions: When administered EPO, TAI + Hx rats had improved behavioural and cognitive performance,
attenuated white matter damage, resolution of neuronal damage spanning from the axon to the dendrite, and
suppressed neuroinflammation, alongside enhanced expression of EpoR. These data provide compelling evidence
of EPO’s neuroprotective capability. Few benefits were observed when EPO was administered to TAI rats without
hypoxia, indicating that EPO’s neuroprotective capacity is bolstered under hypoxic conditions, which may be an
important consideration when EPO is employed for neuroprotection in the clinic.
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Background
Diffuse axonal injury (DAI) is increasingly recognised as a
prominent cause of morbidity and mortality after trau-
matic brain injury (TBI) [1]. DAI is often complicated by
the co-occurrence of secondary hypoxia [2,3], arising from
brain stem injury, airway obstruction, acute respiratory
distress, or cerebral hypoperfusion/hypoventilation [4,5].
Epidemiological studies describe post-traumatic hypoxia
as common sequelae to diffuse injury, worsening neuro-
logical outcome [3,6,7]. Experimentally, hypoxia has been
found to aggravate behavioural outcomes [8-10], exacer-
bate oedema and blood brain barrier (BBB) dysfunction
[11-13], heighten axonal pathology [14,15], and prolong
cerebral inflammation [10,15].
Despite earnest research, no effective therapy has been
developed for the treatment of TBI, with a multitude of
compounds that showed promise in animal studies fail-
ing to exhibit beneficial effects in clinical trials. To date,
more than 20 compounds have been assessed in phase
II/III trials, with none showing long-term benefit [16].
This lack of success in translation from the laboratory to
the clinic has been attributed to several factors, includ-
ing variations in therapeutic doses and administration
windows in animals versus humans, premature passage
to the clinic, failure of experimental models to include
secondary insults that are commonplace in clinical TBI,
and importantly, a lack of research into specifically axo-
noprotective molecules in diffuse TBI models [17].
The haematopoietic agent erythropoietin (EPO) has
garnered interest in recent years as a potential neuropro-
tective treatment in various neuropathologies, in which
EPO has been found to confer a wide range of benefits
on a functional, cellular and biochemical level [18].
Although Epo and its cognate receptor EpoR are en-
dogenously expressed and upregulated under injurious
conditions such as ischemia, hypoxia or TBI [19-21],
their levels of expression rarely appear sufficient to cur-
tail tissue damage and promote neurological recovery
[22]. Therefore, pharmacological treatment with exogen-
ous EPO after CNS injury has been a keen area of inves-
tigation, particularly with respect to focal brain injury,
where EPO has shown to be efficacious in improving
sensorimotor and spatial memory after both controlled
cortical impact injury (CCI) and cryogenic lesion [22-25],
as well as minimising BBB dysfunction and oedema
[23,26]. EPO is also a potent immune modulator, and is
able to reduce levels of the pro-inflammatory cytokines
NFκB, IL-1β, TNF-α, ICAM-1 and CCL-2 in comparison
to vehicle-treated rats when assessed post cortical contu-
sion injury or lateral fluid percussion injury [26-29].
While there is now ample evidence that EPO is benefi-
cial following focal CNS injury, little is known as to the
effects of EPO in limiting the pathology of diffuse TBI,
the most complex and relevant form of brain trauma,
which is associated with high rates of morbidity and life-
long devastating impairments. To date, the therapeutic
effects of EPO have been examined predominantly in an
acute context after diffuse TBI using carbamylated EPO
(CEPO), with administration 30 minutes after impact ac-
celeration injury shown to decrease nitric oxide synthe-
sis at 1 hour, with a subsequent attenuation of oedema
as detected by diffusion-weighted MRI from 2 hours
[30-32]. This one early dose of CEPO was also sufficient
to improve neurological function when examined out to
10 days postinjury [31].
Due to the low risk of adverse outcome and high poten-
tial for benefit, EPO is currently under phase III clinical
trial for TBI with results eagerly anticipated. However, to
date, no studies have examined functional or cellular
changes in experimental diffuse TBI treated with EPO be-
yond the acute setting, and crucially, no studies have
explored the potential for EPO to benefit when TAI is
combined with secondary hypoxia. In light of these find-
ings, we investigated the ability of EPO to improve out-
come after experimental diffuse TBI both alone and in the
context of post-traumatic hypoxia in order to elucidate
EPO’s effects on behavioural and cognitive function,
axonal and dendritic integrity, inflammation, and changes
in the expression of endogenous Epo receptor.
Methods
Model of diffuse traumatic brain injury, post-traumatic
hypoxia and erythropoietin therapy
Animal experiments were conducted in accordance with
the Code of Practice for the Care and Use of Animals
for Scientific Purposes (National Health and Medical
Research Council, Australia), and received approval
from the Alfred Medical Research and Education Precinct
(AMREP) Animal Ethics Committee. Adult male Sprague–
Dawley rats were housed under a 12-hour light/dark cycle
with food and water ad libitum.
The Marmarou model of diffuse traumatic axonal in-
jury (TAI) was used in this study as described by others
and our group [10,15,33]. Rats aged 12 to 16 weeks and
weighing 350 to 375 g on the day of surgery were ran-
domly allocated to one of eight treatment groups, in-
cluding TAI (n = 30), TAI followed by a 30-min systemic
hypoxia (TAI + Hx; n = 30), hypoxia only (n = 30) or
sham surgery (n = 30). After surgery, an equal number of
rats from each group were divided into either vehicle or
EPO treatment. As described previously [15], rats were
anaesthetised with a mixture of 5% isoflurane in 22%
O2/78% N2, endotracheally intubated and mechanically
ventilated with a maintenance dose of 2 to 3% isoflurane
in 22% O2/78% N2. A steel disc of 10-mm diameter and
3-mm thickness was adhered to the skull between the
bregma and lambda suture lines using dental acrylic.
Rats were briefly disconnected from the ventilator and
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placed on a foam mattress (Type E polyurethane foam,
Foam2Size, Ashland, VA, USA) underneath the trauma
device, and a weight of 450 g was allowed to fall freely
through the vertical tube from a height of 2 m. Follow-
ing the impact, rats were reconnected to the ventilator
for a further 30 min using an appropriate concentration
of isoflurane (0.5 to 1%) in either hypoxic (12% O2/88% N2)
or normoxic (22% O2/78% N2) conditions. We have previ-
ously reported the consistent physiological consequences of
this insult resulting in a sO2 of 47 ± 4.3% for the duration
of hypoxia, with a concomitant episode of hypotension,
whereby mean arterial blood pressure was reduced
to 69.5 ± 29.5 mmHg [15]. Hypoxia-only and sham-
operated animals were surgically prepared as described
for TAI rats with the exception of the traumatic impact,
and ventilated with hypoxic or normoxic gas, respect-
ively. After surgery, rats were housed in individual
cages and placed on 37°C heat pads for 24 h to main-
tain normothermia during recovery.
Administration of erythropoietin
At 1 and 24 hours after injury rats were injected intra-
peritoneally (i.p.) with either recombinant human (rh)
EPO-α (5000 IU/kg; Janssen-Cilag, Australia) (hence-
forth referred to as EPO) or the equivalent dose of saline
as previously described [22,27,32]. This dual acute/sub-
acute dosing schedule was chosen due to the respective
benefits of resolution of tissue pathology observed with
acute administration of EPO [34], and the behavioural
benefits observed with a subacute dose [35]. Rats desig-
nated for a 2- or 24-hour survival time received EPO or
saline i.p. 1 hour postinjury only.
Assessment of sensorimotor and cognitive function
Rotarod
Six rats from each treatment group at each time point
were assessed for sensorimotor deficit using the Rotarod
test [36], in which rats must climb on a rotating cylinder
comprising 18 rods (1 mm diameter) (Ratek, Boronia,
VIC, Australia), with the rotational speed increasing in
increments of 3 revolutions per minute (rpm) per 5 sec,
from 0 to 30 rpm. The maximal speed recorded when
the rat was unable to match and slipped from the
Rotarod was taken as the score for each trial. On the
week before surgery, rats were trained on the Rotarod
every second day. After injury, rats were assessed daily
for one week, and every second day for the second week,
concluding at 14 days.
Open field exploration
The open field test was used to assess locomotor activity
as previously described [10]. A separate group of rats were
generated specifically for this and the novel object recog-
nition test (n = 4/group) and were not used for assessment
on the Rotarod or for subsequent histological analysis. At
6 days postinjury, rats were placed in an empty arena
(70 × 70 × 60 cm, W× L ×H) within a dimly lit, closed en-
vironment. Rats were allowed to explore freely for a period
of 15 minutes, with their movement tracked by camera
and the distance walked calculated using a custom-made
automated movement-tracking program.
Novel object recognition test
The novel object recognition test (NORT) examines
short-term episodic recognition memory [37], relying on
the implicit exploratory activity of rodents to discern be-
tween a novel object and one previously encountered
[37-39]. Rats were assessed on day 6 postsurgery, and
first habituated to the arena for 15 minutes. Upon con-
clusion, rats were removed briefly (less than 1 min),
while two identical objects were placed 10 cm away from
the walls in opposing corners of the arena. The rats were
placed back into the experimental chamber and allowed
to explore the objects freely for 15 min (learning phase).
After this, rats were returned to their home cages for a
retention delay of 1 h, during which one familiar object
was replaced with a novel one. Subsequently, rats were
again placed in the area and allowed to explore the ob-
jects for 15 min. Object exploration was scored as nose
or forepaw contact within an area of 2 cm encircling
each object. Rats exploring for less than a cumulative
total of 15 seconds were omitted from analysis (n = 2).
Between trials, objects were cleaned thoroughly with
70% ethanol to eliminate olfactory cues.
Tissue collection
At 1, 7 and 14 days after treatment, those rats previously
assessed on the Rotarod (n = 6 per group per time point)
were killed, and brains were perfusion-fixed using 4%
paraformaldehyde and embedded in paraffin wax. Brain
tissue blocks were cut into 10-μm thick coronal sections
at the level of +0.2 mm and −11.6 mm relative to
bregma and collected onto glass slides.
A separate cohort of rats was generated for assessment
of IL-1β concentration at 2, 24 and 48 h postinjury in brain
homogenates (n = 4 per group per time point). Brains were
divided into left and right hemispheres, the cortex and
cerebellum removed, and the remaining tissue comprising
brainstem, corpus callosum, hippocampus, thalamus and
hypothalamus was combined to from a crude white matter
preparation, and stored at −80°C until use. This allowed
for measurement of IL-1β in brain regions more suscep-
tible to diffuse injury and axonal damage.
Measurement of the corpus callosum area
Three consecutive brain sections were dewaxed, rehy-
drated, stained using hemotoxylin and eosin, and visua-
lised under a light microscope (Olympus BX50; Olympus,
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Mt Waverley, VIC, Australia). Brains were photographed
at low power (2x objective) to cover the entire section.
The whole brain area and the area of the corpus callo-
sum were measured using ImageJ (v. 1.45; National
Institutes of Health, Bethesda, MD, USA), and the area
of the corpus callosum was expressed as the percentage
of total brain area.
Immunohistochemistry
Immunohistochemistry was performed on three con-
secutive sections per region of interest per animal
using the following primary antibodies: neurofilament
heavy-chain (NF-200, 1:1000, Zymed, Carlsbad, CA, USA),
microtubule-associated protein 2 (MAP2, 1:200, Millipore,
North Ryde, N.S.W., Australia), membrane-bound EPO
receptor (EpoR, 1:150, Santa Cruz Biotechnology, Dallas,
TX, USA), CD68 (1:150, Millipore). All staining was visua-
lised using diaminobenzidine (DAB) as the chromagen,
following incubation with appropriate secondary antibodies
and reagents provided in the peroxidase ABC kit (Vector
Laboratories, Burlingame, CA, USA) as described earlier by
our group [15].
To determine which cell types expressed EpoR and
whether EPO treatment induced EpoR expression, double
labelling immunofluorescence was performed using anti-
bodies to EpoR in conjunction with NF-200, CD68, NeuN
(neurons, 1:1000, Chemicon, Billerica, MA, USA) or GFAP
(astrocytes, 1:1000, Dako Cytomation, Glostrup, Denmark).
Sections were incubated simultaneously with each marker
overnight at 4°C, and labelled cells were visualised by incu-
bation with fluorescent-tagged secondary antibodies (1:200
goat anti-rabbit Alexa 594 (red) and 1:200 goat anti-rabbit
Alexa 488 (green); Invitrogen, Carlsbad, CA, USA).
Analysis of immunohistochemistry
All sections stained with NF-200, MAP2, EpoR and CD68
were visualised using light microscopy, with the exception
of double labelling experiments, which were analysed
using fluorescence microscopy (Olympus BX50).
Brain sections were photographed using a digital camera
(Olympus DP71) with AnalySIS life science software
(Olympus). Quantitative analysis of the micrographs was
performed using ImageJ software. Multiple photographs
were taken to cover the entire corpus callosum (for NF-
200, EpoR and CD68) and lateral septal nucleus (MAP2) at
the level of +0.2 mm to bregma, and pyramidal tracts at
−11.6 mm to bregma) in the case of NF-200 and EpoR.
Three sections were examined per region for each brain,
with cell counts (in the case of NF-200, EpoR and CD68)
averaged per section for each animal. Densitometric ana-
lysis of MAP2 immunohistochemistry was performed in a
region of interest in the lateral septal nucleus, correspond-
ing to an area of 1.43 mm2. Measurements were performed
over three consecutive sections per brain using ImageJ
software.
IL-1β measurement
White matter preparations were homogenised in an
extraction solution containing Tris–HCl (50 mmol/L,
pH 7.2), NaCl (150 mmol/L), 1% Triton X-100, and
1 μg/mL protease inhibitor cocktail (Complete tablet;
Roche Diagnostics, Basel, Switzerland) and agitated for
90 min at 4°C. Tissue homogenates were then centri-
fuged at 2,000 rpm for 10 min, and the supernatant
stored at −80°C until use. The concentration of IL-1β
was determined using a rat IL-1β ELISA (R&D Systems,
Minneapolis, MN, USA) with samples run undiluted in
duplicate, and incubated on pre-coated plates. The op-
tical density of each well was measured at 450 nm, with
a wavelength correction of 540 nm (as suggested by the
manufacturer). The concentration of IL-1β was calcu-
lated against the standard curve. Total protein concen-
trations were determined for each sample using the
Bradford Assay (Bio-Rad Laboratories, Hercules, CA,
USA) and the concentration of IL-1β expressed as pico-
gram per milligram of total protein.
Data analysis
Statistical analysis was performed using a commercially
available software package (GraphPad Prism version 5.0
for the Macintosh; GraphPad, La Jolla, CA, USA). Re-
sults from the Rotarod test were analysed using a two-
way repeated measures ANOVA, and where initial
significant changes were observed with regards to treat-
ment, time and interaction between the two factors,
Bonferroni post-hoc analysis was performed. Immunohis-
tochemistry, callosal area and IL-1β data were analysed
by two-way ANOVA, also with Bonferroni post-hoc ana-
lysis where appropriate. Data from the open field explor-
ation was analysed by one-way ANOVA with post-hoc
Bonferroni analysis, while preferences for familiar versus
novel objects in the NORT was analysed using a t-test.
Data were presented as mean ± standard error of the mean
and were considered significant where P <0.05. P values
are indicative of Bonferroni post-hoc analysis unless other-
wise indicated.
Results
Erythropoietin promotes significant improvement in
motor function after TAI + Hx
Both TAI and TAI + Hx treatment groups demonstrated
a severe sensorimotor deficit on the Rotarod 1 day
postinjury when compared to sham, with scores of
9.58 ± 1.40 rpm and 9.3 ± 2.09 rpm (Figure 1A,B, re-
spectively). Similar scores were also achieved at this
time when either group was administered EPO. When
Rotarod scores were assessed across groups using two-
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way RM ANOVA, there was a significant effect of treat-
ment and time, and a significant interaction between
the two (P <0.001).
As shown in Figure 1A, over the course of 14 days
TAI rats steadily improved in motor function. TAI +
EPO rats showed a comparable degree of recovery in
their Rotarod performance compared to their TAI-
vehicle counterparts, with scores remaining similar in
each group until 14 days. The Rotarod scores observed
in TAI + Hx and TAI + Hx + EPO rats were also similar
to each other and to the TAI groups at 1 day (9.3 ±
2.09 rpm versus 10.44 ± 1.73 rpm, respectively, Figure 1B),
with an equal rate of improvement between groups until
day 4. During this acute phase, the maximal speed
achieved by each TAI +Hx group was significantly slower
than sham control rats (day 4: 16.12 ± 1.66 rpm, TAI +Hx
and 16.23 ± 2.7 rpm, TAI +Hx + EPO versus 28.25 ±
1.12 rpm, sham; P <0.05). However, at 5 days postinjury
TAI +Hx + EPO rats made a remarkable functional im-
provement, and at 6 days were performing significantly
better on the Rotarod than the TAI +Hx rats (24.0 ± 2.0
versus 14.25 ± 1.98, P <0.05). By 10 days, TAI +Hx + EPO
rats had returned to sham-level scores (P <0.05), with sig-
nificant differences to TAI +Hx rats on days 10, 12 and
14. Conversely, untreated TAI +Hx rats showed a plateau
in recovery at 8 days post-injury, with scores of 17.25 ±
3.94 rpm, and still maintained a significantly greater deficit
compared to sham (28.5 ± 1.50 rpm, P <0.05).
Erythropoietin improves travel distance in open field
exploration in TAI + Hx rats
When assessed in the open field at 6 days postsurgery,
sham and hypoxia rats travelled a similar distance within
15 min (Figure 2A). While after TAI, rats showed a sig-
nificant impairment, and were only able to travel half of
the distance achieved by sham animals (23.38 ± 4.36 m
versus 44.26 ± 6.40, respectively, one-way ANOVA: effect
of treatment P = 0.0068; Bonferroni post hoc, P <0.05).
EPO treatment failed to improve this deficit in TAI +
EPO rats, which maintained distances travelled identical
to TAI vehicle control animals (P <0.05).
The addition of hypoxia after TAI further reduced the
distance travelled below that of TAI alone by 15%, with
a mean distance of 19.90 ± 5.62 m; a value also signifi-
cantly below that observed for sham rats (P <0.05,
Figure 2B). Conversely, when treated with EPO, TAI +
Hx rats had a significant increase in their travel dis-
tances to more than double that of their vehicle- treated
counterparts (P <0.05), which returned them to sham
values.
Erythropoietin improves recognition of the novel object
after TAI + Hx, but not after TAI alone
In the learning phase, rats of all groups showed no pref-
erence for either of the identical objects with all injured
rats exploring for approximately half of the total explor-
ation time of sham controls whether treated with vehicle
or EPO (data not shown). As depicted in Figure 2C, in
the recall phase of testing, sham rats spent a significantly
larger proportion of time exploring the novel object
compared to the familiar, with a mean value of 74% of
Figure 1 Erythropoietin (EPO) promotes significant
improvement in motor function in rats subjected to traumatic
axonal injury with hypoxia (TAI + Hx), but not in traumatic
axonal injury (TAI) alone. Rats were trained on the Rotarod task for
7 d prior to injury, then tested daily for 6 d after surgery and on
every second day until 14 d. (A) The deficit observed after TAI and
TAI + EPO rats was similar 1 d postinjury. TAI rats made a steady
recovery and improved throughout the course of the 2-week testing
period; however there was no additional improvement after EPO
treatment. (B) Both TAI + Hx and TAI + Hx + EPO groups achieved
identical rpm scores on the Rotarod until 4 d postinjury, from which
point TAI + Hx + EPO rats were performing significantly better on the
Rotarod by 6 d than TAI + Hx rats. By 10 d, TAI + Hx + EPO rats
reached an rpm similar to sham, with this beneficial effect
maintained out to the end of the testing period. Data shown as
mean ± SEM. N at 1 day = 24/group; 2 to 6 days = 12/group; 8 to
14 days = 6/group. Data was analysed by 2-way ANOVA repeated
measures with Bonferroni post hoc test, with a P value of <0.05
considered significant.
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total exploration spent on the novel object, and only
24% spent on the familiar object (P <0.001, familiar (F)
versus novel (N), one-way ANOVA with Bonferroni post
hoc analysis). Rats exposed to hypoxia alone also spent a
significant proportion of time exploring the novel object
compared to the familiar, with near-identical ratios
to those observed for sham (P <0.05, F versus N). Con-
versely, TAI rats spent a similar proportion of time ex-
ploring the novel object and familiar, with no significant
difference observed between TAI rats with (P = 0.72,
F versus N) or without EPO treatment (P = 0.27, F versus
N, Figure 2C).
Similarly, to TAI, rats subjected to TAI + Hx did
not show an object preference and spent similar pro-
portions of time exploring both the familiar and the
novel object (P = 0.76, F versus N, Figure 2D), pre-
senting scores of 45% and 55% for the familiar and
novel objects, respectively. However, when TAI + Hx
rats were administered EPO, a substantial shift in
memory function was observed, with rats spending a
significantly elevated proportion of time exploring the
novel object for 75% of the total exploration time
when compared to the previously encountered object
(P <0.05, F versus N).
TAI and TAI + Hx induced atrophy of the corpus callosum
is reversed by erythropoietin treatment
The corpus callosum is particularly vulnerable to
TAI, revealing extensive axonal pathology, which is
exacerbated following post-traumatic hypoxia [15].
Therefore, we determined whether there were any
changes in the area of the corpus callosum after in-
jury, and whether EPO was able to attenuate any tis-
sue loss. Following sham surgery (Figure 3A),
hypoxia (B) and TAI (C,G), the area of the corpus
callosum remained unchanged at 1, 7 and 14 days;
however TAI rats demonstrated a significant increase
in area of the corpus callosum after EPO treatment
(D) relative to sham at 1 day (P <0.05) and to sham
and vehicle treated TAI rats at 7 days (P <0.05). A
clear effect of TAI + Hx was observed 1 day postin-
jury compared to sham rats, with the corpus
Figure 2 Erythropoietin (EPO) therapy improves motor deficit and restores spatial memory in rats with post-traumatic axonal injury
(TAI) hypoxia (Hx). (A) At 6 d postinjury, TAI rats travelled significantly shorter distances in the testing arena over 15 min with or without EPO
treatment. (B) TAI + Hx rats covered slightly shorter distances than TAI rats, and were significantly impaired compared to sham. However, when
treated with EPO, TAI + Hx rats had a remarkable recovery, with distances traveled significantly improved to those seen in sham rats. (C) The
novel object recognition test (NORT) was used to assess memory retention. (A) In the recall phase of testing, sham and hypoxia treated rats
spent a significant proportion of their total exploration time on the novel object however this recognition was lost after TAI. Administration of
EPO to TAI rats did not improve the proportion of time spent exploring the novel object. (D) TAI + Hx rats also appeared to have no recollection
of the familiar object, spending identical proportions of time exploring both the novel and familiar objects over 15 min. EPO significantly reversed
memory dysfunction and returned values back to those observed for sham. Data are expressed as mean ± SEM, n = 4/group. *P <0.05 when
analysed by 1-way ANOVA with Bonferroni post-hoc test.
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Figure 3 Atrophy of the corpus callosum is restored with erythropoietin (EPO) therapy in traumatic axonal injury with hypoxia (TAI + Hx)
rats. Atrophy of the corpus callosum after injury was quantified on days 1, 7 and 14 after TAI and TAI + Hx with and without EPO. Photomicrographs
taken 1 day postinjury depict treatment effects in the corpus callosum: Sham (A) and hypoxia (B) rats showed no change in callosal area over the
course of 14 days. (C,G) There was no change in the measureable area of the corpus callosum after TAI, however there was a significant increase in the
callosal area of TAI rats after EPO treatment at 1 and 7 d (D,G) when compared to sham, and at 7 d when compared to TAI. (E,H) TAI + Hx rats had a
significant decrease in the area of the corpus callosum at 1 d when compared to sham. (F) With EPO treatment, area of the corpus callosum was
significantly increased in TAI + Hx rats at 1 (pictured), 7 and 14 d when compared to vehicle TAI + Hx or sham controls. Data are expressed as mean ±
SEM, n = 6/group. Letters matched to letters with apostrophes indicate a significant difference (P <0.05 by 2-way ANOVA with post-hoc Bonferroni test).
Scale bar = 2 mm.
Hellewell et al. Journal of Neuroinflammation 2013, 10:156 Page 7 of 21
http://www.jneuroinflammation.com/content/10/1/156
callosum significantly diminished to 82% of sham values (P
<0.05, two-way ANOVA with Bonferroni post-hoc analysis,
Figure 3E,H). When treated with EPO, TAI + Hx rats had a
significant 36% increase in callosal area at 1 day compared
with vehicle-treated TAI +Hx rats (2.04 ± 0.21 versus 1.3 ±
0.08, in TAI +Hx + EPO versus TAI +Hx, respectively, P
<0.05, Figure 3F). Interestingly, the area of the corpus callo-
sum of TAI +Hx + EPO rats was also 23% larger compared
to sham rats (2.04 ± 0.21 versus 1.58 ± 0.09, P <0.05). At 7
d, the reduction in callosal area seen in TAI +Hx rats per-
sisted, with values remaining below that of sham. Con-
versely, TAI +Hx + EPO rats maintained the integrity of
the corpus callosum at 7 days, with values remaining sig-
nificantly elevated over sham or TAI +Hx (2.04 ± 0.19 ver-
sus 1.39 ± 0.06 and 1.58 ± 0.09, TAI +Hx and sham,
respectively; P <0.05) at 7 days. This increase was still evi-
dent at 14 days, where the corpus callosum of TAI +Hx +
EPO rats remained significantly larger than sham (P <0.05).
Axonal pathology in the corpus callosum is significantly
reduced by erythropoietin in TAI + Hx rats
Axonal damage was assessed using the NF-200 heavy-
chain marker, which highlights the gross pathology of
diffuse axonal injury in the form of swollen axons and
terminal bulb formation [40]. In sham (Figure 4A) and
hypoxia animals (not shown), scant NF-200 positive
staining was observed at all time points, with almost no
positive bulbs or axons counted after surgery.
Generally, axonal damage after TAI or TAI +Hx was
similar to that we previously reported in this combined
insult model with respect to regional distribution through
the white matter and achieving a particular prominence in
the corpus callosum and pyramidal tracts of the brainstem
[15]. Axonal pathology was most striking in TAI and
TAI +Hx groups 1 day postinjury (Figure 4B,D, respec-
tively), with the presence of both spherical terminal axonal
bulbs and long, tortuous axons.
Axonal pathology in the corpus callosum
In the corpus callosum, the largest numbers of axonal
bulbs counted in each section were observed acutely at
1 day after TAI (159.6 ± 43.99; Figure 4F), with numbers
of bulbs gradually decreasing at 7 days (75.7 ± 21.69)
and remaining constant until 14 days (61.0 ± 33.65), with
a significant effect of time overall observed by two-way
ANOVA (P <0.01).
In TAI rats treated with EPO, numbers of axonal
bulbs were similar to those observed in vehicle-treated
rats at 1 and 7 days (152.10 ± 39.96 and 91.47 ± 48.56,
respectively; Figure 4C). Interestingly, at 14 days after
TAI with EPO treatment, there was an increase (though
not significant) in the numbers of axonal bulbs when
compared to either TAI rats at 14 days, or TAI + EPO
rats at 7 days (205.7 ± 105.9 versus 61.0 ± 33.65 or
91.47 ± 48.56, respectively).
In TAI rats, numbers of swollen axons were also high-
est at 1 day, with similar numbers detected irrespective
of vehicle or EPO treatment (33.48 ± 12.32 versus 40.75
± 14.07 in TAI versus TAI + EPO, Figure 4G). While
there was a gradual decline in numbers of swollen axons
in TAI rats over the course of 2 weeks, EPO treatment
only resulted in a slight decrease in axonal damage at
7 days, persisting out to 14 days (30.22 ± 13.64 versus
8.313 ± 7.04, TAI + EPO versus TAI at 14 days). Overall,
there was no statistically significant difference in axonal
pathology with respect to either axonal bulbs or swollen
axons detected between TAI and TAI + EPO rats at any
time point examined.
With a substantially more severe injury caused by add-
itional post-traumatic hypoxia, TAI +Hx rats suffered a
greater burden of axonal damage, particularly in the form
of axonal bulbs, which were detected more than three-
fold higher than that observed in TAI alone on day 1.
Similar to TAI animals, axonal bulbs were most promin-
ent at 1 day after TAI +Hx injury (Figure 4H) with a
decline by approximately two-thirds by 7 days, and by
two-thirds again by 14 days (503.6 ± 222, 155.5 ± 82.77,
43.19 ± 12.21 at 1, 7 and 14 days, respectively). Overall,
there was a significant effect of EPO treatment on mini-
mising the number of axonal bulbs over the time course
examined (P <0.01 by two-way ANOVA), with the most
prominent reduction of axonal bulbs of 64% by EPO
observed at 1 day after TAI +Hx (503.6 ± 222.0 versus
181.8 ± 83.54 for TAI +Hx versus TAI +HX+ EPO, re-
spectively, P <0.05). A significant decrease of 83% was also
seen at 7 days after injury, when axonal pathology was
largely diminished in TAI +Hx + EPO rats, while it per-
sisted in TAI +Hx rats (155.5 ± 82.77 versus 27.76 ± 18.83,
P <0.05). However, at 14 days, numbers of axonal bulbs
were similar in both TAI +Hx and TAI +Hx + EPO rats,
with no significant difference observed between the two
groups (43.19 ± 12.21 versus 36.21 ± 11.46, P = 0.68).
Examination of axonal swelling via NF-200 staining
in TAI + Hx rats also demonstrated abundant pathology
throughout the corpus callosum, and although maximal
at 1 day postinjury, the numbers of swollen axons
were substantially less when compared to numbers of
axonal bulbs. EPO treatment reduced the numbers of
swollen axons by 65% (136.1 ± 70.65 versus 47.14 ±
28.46; Figure 4I) though this effect was not statistically
significant. TAI + Hx + EPO rats also experienced a de-
crease in axonal swelling at 7 days, with a reduction of
77% compared to vehicle (35.43 ± 28.87 versus 8.26 ±
6.13), though again this was not statistically significant.
At 14 days, axonal pathology was largely diminished in
both TAI + Hx and TAI + Hx + EPO groups, with scant
numbers of damaged axons detected.








Figure 4 (See legend on next page.)
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Axonal pathology in the brainstem
In the brainstem, analysis of NF-200 immunohistochem-
istry revealed extensive axonal pathology, particularly
with respect to the pyramidal tracts in which abundant
axonal bulbs and swollen axons were detected, mostly at
1 day postinjury. In keeping with findings in the corpus
callosum, no axonal pathology was detected in sham or
hypoxia only animals at any time point examined.
TAI rats had significantly more axonal bulbs in the
pyramidal tracts when compared to the corpus callosum.
This was detected particularly at 1 day postinjury, where
there was an increase of 66% in the pyramidal tracts
(466.3 ± 123.5 versus 33.48 ± 12.32, P <0.05). The num-
ber of axonal bulbs in TAI rats decreased over 7 days
(466.3 ± 123.5 versus 133.4 ± 31.26, P <0.05), to remain
constant until 14 days (185.50 ± 68.98; Figure 5A). In
EPO treated TAI rats, a small, nonsignificant decrease in
the number of axonal bulbs was observed at 1 day, rela-
tive to TAI alone (466.3 ± 123.5 versus 270.5 ± 196.2,
P = 0.43), with the number of bulbs remaining un-
changed over the course of 14 days.
The number of swollen axons observed in TAI rats
was highest in the brainstem at 1 day (Figure 5B). The
number of swollen axons was significantly decreased
over time in the pyramidal tracts of TAI rats at 7 day
(25.78 ± 8.53 versus 6.52 ± 3.87, P <0.05), with relatively
similar numbers of swollen axons observed at 14 day.
EPO treatment did not show any effect in reducing the
(See figure on previous page.)
Figure 4 Axonal pathology in the corpus callosum is significantly reduced by erythropoietin (EPO) after traumatic axonal injury with
hypoxia (TAI + Hx). Representative photomicrographs from the corpus callosum demonstrating axonal bulbs (black arrows) and swollen axons
(white arrows) using the NF-200 marker at 1 d following sham (A), TAI (B), or TAI + Hx (D) surgery. (C) When treated with EPO, TAI rats did not
have any reduction in axonal pathology, however TAI + Hx rats (E) were afforded remarkable reduction of axonal bulbs when treated with EPO.
Scale bar = 100 μm. (F) Number of axonal bulbs in the corpus callosum of TAI rats 1, 7 and 14 d postinjury with vehicle or EPO treatment. No
benefit of EPO was observed in after TAI. (G) Number of swollen axons in the corpus callosum of TAI rats 1,7 and 14 d postinjury with either
vehicle or EPO treatment. Again, no differences were observed in swollen axons between TAI or TAI + Hx at any time point. (H) Number of axonal
bulbs counted in the corpus callosum after TAI + Hx with/without EPO treatment at 1, 7 and 14 d, demonstrating a significant beneficial effect of
EPO at 1 and 7 d (*P <0.05; 2-way ANOVA with post-hoc Bonferroni test). (I) Although there was a decrease in the number of swollen axons in
the corpus callosum of rats allocated to TAI + Hx or TAI + Hx + EPO treatment at 1, 7 or 14 d, this was not statistically significant. Data shown as
mean ± SEM, n = 6 per group per time point.
Figure 5 Erythropoietin (EPO) attenuates axonal pathology in the pyramidal tracts of the brainstem. (A) Axonal bulbs in the pyramidal
tracts of the brainstem in traumatic axonal injury (TAI) rats with/without EPO treatment at 1, 7 or 14 d. No statistical difference was observed at
any time point amongst the treatment groups, however there was a spontaneous decrease in the number of axonal bulbs at 7 d in TAI rats only.
(B) Number of swollen axons in the pyramidal tracts of TAI and TAI + EPO rats at 1, 7 and 14 d. EPO treatment failed to reduce axonal swelling,
however there was an overall decrease in the number of swollen axons in TAI rats at 7 d. TAI + Hx rats had a strikingly more axonal bulbs (C) and
swollen axons (D) in the pyramidal tracts of the brainstem, with both substantially (though not significantly) reduced at 1 d by treatment with
EPO. Data shown as mean ± SEM, n = 6 per group per time point.(*P <0.05, 2-way ANOVA with post-hoc Bonferroni test).
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number of swollen axons at any time point examined
when administered after TAI.
TAI + Hx rats also showed the highest number of
axonal bulbs in the brainstem at 1 day post-injury, with
a decrease of 62% at 7 days (to 286.70 ± 71.90), and
a further decrease by 78% at 14 days (to 64.40 ± 24.55;
Figure 5C), though this was not statistically significant.
When treated with EPO, TAI + Hx rats had a decrease in
number of NF-200 positive axonal bulbs of 64%, at 1 day
postinjury, however this was not statistically significant
(767.8 ± 353.4 versus 263.3 ± 70.17, P = 0.21).
TAI +Hx + EPO rats also had a marked decrease in the
number of swollen axons at 1 day in the pyramidal tracts
when compared to untreated TAI +Hx rats (Figure 5D)
and although not statistically significant, the mean reduc-
tion of axonal swellings exceeded 90% (149.8 ± 102.4 ver-
sus 15.62 ± 6.892, P = 0.94). The number of swollen axons
was substantially decreased in vehicle TAI +Hx rats at
7 days, with a further decline at 14 days, while the number
of swollen axons re- mained relatively constant in TAI +
Hx + EPO rats up to 14 days.
Dendritic loss in TAI + Hx rats is largely rescued by
erythropoietin therapy
Dense MAP2 immunoreactivity was found throughout
the brains of sham animals localised to the soma and
proximal dendrites of neurons, with scant expression in
the white matter (Figure 6A). In TAI rats, MAP2 immu-
nohistochemistry revealed a diffuse loss in staining, al-
though the cytoarchitecture was maintained in the
neuronal soma and dendrites (Figure 6B). Using densito-
metric analysis, the reduction in MAP2 was most prom-
inent at 1 day in the lateral septal nucleus of TAI rats
when compared to sham using densitometric analysis
(11.47 ± 0.72 versus 18.4 ± 2.33, P <0.05; Figure 6F).
When TAI rats were treated with EPO, a significant pres-
ervation of MAP2 density was observed at 1 day (17.59 ±
3.27 versus 11.47 ± 0.72, P <0.05 TAI + EPO versus TAI),
with values similar to sham levels (Figure 6C,F). TAI rats
showed no change in MAP2 density over time (up to
14 days), while interestingly, TAI + EPO rats had a small,
though non-significant decrease of 40% in MAP2 density
over the course of 14 days.
TAI +Hx rats demonstrated remarkable changes both in
the intensity of MAP2 staining and the integrity of the
cytoarchitecture, with large regions of the lateral septal
nucleus completely devoid of MAP2 immunoreactivity in
a ‘stripe-like’ pattern at 1 day postinjury (Figure 6D), at
which time there was a significant decrease to approxi-
mately half of the MAP2 density observed for sham ani-
mals (9.64 ± 1.2 versus 18.4 ± 2.33, P <0.05, Figure 6G). At
7 days, there was a small recovery in MAP2 loss in TAI
+Hx rats, with a trend to significance (9.64 ± 1.20 versus
12.90 ± 0.69, P = 0.06; Figure 6G). At 14 days, values were
comparable to those observed at 7 days, with no further
recovery in MAP2 density in vehicle TAI +Hx rats.
TAI +Hx rats treated with EPO showed the most striking
recovery of MAP2 density at 1 day (9.64 ± 1.20 versus
17.33 ± 2.16, P <0.05; Figure 6E,G), with values observed
significantly higher than TAI + Hx, and similar to sham.
This effect of EPO in maintaining MAP2 density was also
observed at 7 and 14 days, with values in TAI + Hx +
EPO rats remaining similar to sham and significantly
higher than vehicle-treated groups at every time point
examined.
Erythropoietin administration enhances the expression of
erythropoietin receptor
Baseline cellular expression of the EpoR was found
throughout the brains of sham and hypoxia animals, with
no obvious specificity in distinct brain regions. In injured
animals, EpoR expression was enhanced throughout the
white matter, overlapping with axonal damage in the pyr-
amidal tracts of the brainstem and the corpus callosum, in
which positively stained cells appeared to be mostly small
and membrane-bound.
EpoR expression in the corpus callosum
In the corpus callosum, TAI rats had a significant increase
in the number of cells expressing the EpoR at 1 day postin-
jury (62.64 ± 22.11 versus 7.42 ± 2.34, P <0.05, Figure 7A),
which increased further, albeit nonsignificantly at 7, and
at again at 14 days relative to 1 day, to reach a peak of
166.40 ± 120.20 EpoR positive cells. With EPO treatment,
the number of EpoR positive cells was slightly but signifi-
cantly higher over sham at 1 day post-injury, and further
increased significantly to peak at 7 days (174 ± 55.13 versus
35.53 ± 8.28, TAI + EPO 7 days versus 1 day, respectively;
P <0.05). EpoR expression subsided at 14 days in TAI +
EPO rats, with values similar to those observed at 1 day
post-injury.
At 1 day postinjury, TAI + Hx rats had a significant in-
crease in number of cells expressing the EpoR in the
corpus callosum (Figure 7B, P <0.05), with a comparable
number of cells to TAI rats at this time. TAI + Hx rats
experienced a peak in the numbers of cells expressing
EpoR at 7 days, with a significant increase from 1 day
(223.0 ± 52.55 versus 71.81 ± 21.74, P <0.05). In these
rats, EpoR expression had decreased by 14 days, with
similar numbers to 1 day. Regardless of whether rats had
vehicle or EPO treatment, an almost identical pattern of
EpoR expression was obtained in the corpus callosum of
all TAI + Hx rats, displaying a peak at 7 days.
EpoR expression in the brainstem
Examination of EpoR staining in the brainstem revealed
increased expression of EpoR across all groups com-
pared to the corpus callosum, regardless of treatment.
Hellewell et al. Journal of Neuroinflammation 2013, 10:156 Page 11 of 21
http://www.jneuroinflammation.com/content/10/1/156
Sham and hypoxia-only rats had a comparable basal
expression of EpoR in the pyramidal tracts of the brain-
stem at 1 day (Figure 7E). At day 1, TAI rats revealed a
small, non-significant increase in the number of cells ex-
pressing the EpoR (Figure 7C) when compared to either
sham or hypoxia treatments. Interestingly, at 7 days the
number of cells expressing EpoR remained similar to
that observed at day 1 in the pyramidal tracts, and a
peak in EpoR expression was delayed to 14 days postin-
jury, with double the number of EpoR positive cells
when compared to TAI rats at 7 days, sham or hypoxia
rats (341.10 ± 83.52 (TAI 14 days) versus 174 ± 58.23
(TAI 7 days), 103.80 ± 43.24 (sham), or 77.67 ± 28.97
(hypoxia); P <0.05 TAI 14 days versus sham, hypoxia
only, Figure 7C). Upon EPO administration, TAI rats did
not show increased number of cells expressing the EpoR
at 1 day; however at 7 days, there was a substantial in-
crease of EpoR positive cells, with a statistical trend for
increase over TAI vehicle rats (391.0 ± 118.70 versus
174 ± 58.23, P = 0.09). By 14 days, this number had
slightly decreased and was akin to peak values observed
for vehicle TAI rats, though it remained significantly
higher when compared to sham or hypoxia rats
(P <0.05).
Figure 6 Loss of dendrites is regionally variable in traumatic axonal injury (TAI) and traumatic axonal injury with hypoxia (TAI + Hx)
rats, and is largely rescued by erythropoietin (EPO). (A) Representative photomicrograph of dense MAP2 immunoreactivity observed in the
lateral septal nucleus of a sham-treated rat. (B) 1 d after TAI, there was a diffuse loss of MAP2 staining, although the cytoarchitecture remained
similar to sham. (C) EPO treatment improved the appearance of MAP2 reactivity in the lateral septal nu. (D) Striking changes in MAP2 staining
were observed in TAI + Hx rats, in which changes both in the intensity of MAP2 staining with regions completely devoid of MAP2 immunoreactivity.
(E) EPO markedly rescued dendritic loss in TAI + Hx + EPO rats. Scale bar = 100 μm. (F) Densitometric analysis of TAI rats revealed a decrease in MAP2
labeling at 1 d compared to sham, and was significantly improved by EPO treatment. (G) TAI + Hx rats had a more substantial loss of MAP2 1 d
postinjury, and EPO treatment significantly restored MAP2 density to sham levels. With this protective effect maintained at 7 and 14 d. Data shown
as mean ± SEM, n = 6 per group per time point. *P <0.05, 2-way ANOVA with post-hoc Bonferroni test.
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In TAI + Hx rats at 1 day postinjury, there was a simi-
lar level of EpoR expression compared to sham, hypoxia
and TAI rats, with no discernable increase in positive
cells (Figure 7D,F). However, at day 7, a sudden increase
in EpoR expression occurred, reaching a peak value
greater than at 1 day (463.60 ± 155.10 versus 147.80 ±
16.18, TAI + Hx 7 days versus 1 day, P = 0.05; P <0.05,
TAI + Hx 7 days versus sham), with a reduction to con-
trol levels at 14 days.
Interestingly, upregulation of EpoR in TAI + Hx + EPO
rats occurred earlier, at 1 day postinjury (Figure 7G),
with the number of EpoR positive cells being signifi-
cantly higher than those seen in sham, hypoxia, TAI or
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Figure 7 Erythropoietin (EPO) administration enhances the expression of the erythropoietin receptor (EpoR) in the brainstem of
traumatic axonal injury with hypoxia (TAI + Hx) rats. (A) In the corpus callosum, TAI rats had a significant elevation in EpoR numbers over
sham at 1,7 and 14 days, with similar numbers observed in TAI + EPO rats over this time course. (B) TAI + Hx and TAI + Hx + EPO treatments both
resulted in increased numbers of positive cells at 1 day compared to sham, with both groups peaking at 7 days before returning to sham levels
at 14 days. (C) TAI and TAI + EPO rats showed a similar expression pattern of EpoR in the brainstem at 1 d, however at 7 d, TAI + EPO rats had a
substantial increase in the number of cells staining positively for EpoR. (D) No increase in EpoR positive cells was observed in the pyramidal tracts
at 1 d after TAI + Hx; however in these rats, EPO administration induced a significant increase in EpoR expression. At 7 d, the number of EpoR-
positive cells increased in TAI + Hx similarly to TAI + Hx + EPO. Letters matched to letter with apostrophe indicate a significant difference, P <0.05;
2-way ANOVA with post-hoc Bonferroni test. Data expressed as mean ± SEM, n = 6/group. *(E) Photomicrograph demonstrating low level of EpoR
expression in the pyramidal tracts after sham surgery, a mild increase in TAI + Hx (F), and a significant increase in EpoR-positive cells in TAI + Hx +
EPO rats (G). Scale bar = 100 μm.
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increased EpoR expression was maintained in TAI +
Hx + EPO rats at 7 days, while by 14 days, numbers of
EpoR positive cells in TAI + Hx + EPO rats declined to
values similar to those of TAI + Hx rats.
The erythropoietin receptor is expressed predominantly
on neurons
To determine the type of cells expressing EpoR, immuno-
fluorescent double labelling was employed on brain sec-
tions at various times in combination with markers for
neurons (NeuN), damaged axons (NF-200), macrophages/
microglia (CD68) and astrocytes (GFAP). In the pyramidal
tracts, there was a strong co-localisation between EpoR and
NeuN at 1 day post-TAI (Figure 8 panel A), with high ex-
pression in neurons throughout the brain regardless of
treatment. No overlap was seen between EpoR and NF-200
staining at 1 (pictured) or 7 days post-TAI, confirming that
EpoR was not expressed on damaged axons (8B). CD68
staining for macrophages and microglia revealed a partial
colocalisation with EpoR staining at 7 days in a small per-
centage of CD68 positive cells distributed in the corpus cal-
losum (8C). Examination of GFAP staining 1 day postinjury
showed no overlap with EpoR in the corpus callosum (8D)
or any other region of the brain. To ensure the staining
visualised was specific, appropriate controls were carried
out omitting the primary antibody for each marker. Panel E
Figure 8 The erythropoietin receptor (EpoR) is expressed predominantly on neurons. Representative images of immunofluorescent double
labeling employed to determine co-localisation between EpoR (middle panel) and neurons (A; NeuN), damaged axons (B; NF-200) in the brainstem at
1d, macrophages/microglia (C; CD68), and astrocytes (D; GFAP) in the corpus callosum at 7 d. EpoR co-localised mostly with NeuN, having a sporadic
overlap with CD68. No colocalisation was found for EpoR and NF-200 or GFAP. (E) Demonstrates a lack of positive staining in negative control slides.
Scale bar = 100 μm.
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demonstrates a lack of positive staining in these negative
control slides (8E).
Accumulation of CD68 positive macrophages and
microglia is reduced by erythropoietin treatment after
TAI + Hx
Analysis of brain sections from sham and hypoxia rats re-
vealed low numbers of CD68 positive cells throughout the
brain at each time point examined. At 7 days postinjury,
there was a marked increase in accumulation of CD68
positive cells in TAI brains which was most prominent in
the corpus callosum, concomitant to axonal damage.
CD68 positive cells were classified and quantified as being
of a microglial or macrophage appearance based on the
presence/absence of processes and amoeboid morphology
as previously described [15]. At 7 days post TAI, rats had
similar numbers of CD68 positive macrophages and
microglia, with both significantly elevated when compared
to sham (Figure 9A, P <0.05). At 14 days, the numbers
of both cell types increased slightly but non-significantly
(P = 0.34 for macrophages and P = 0.65 for microglia) and
maintained a relative constant ratio to each other, to reach
peak numbers of 105.50 ± 40.24 (macrophages) and
108.60 ± 54.19 (microglia), respectively.
Interestingly, while CD68 positive macrophages were
highest in number in the corpus callosum of TAI rats at
14 days, EPO treatment resulted in an earlier peak in
macrophage accumulation at 7 days, with counts signifi-
cantly higher than those observed for vehicle-treated
rats P <0.05; Figure 9A). This relationship was inverse at
14 days, at which time EPO-treated TAI rats had a sharp
decrease in macrophages to approximately one-third,
although this did not reach statistical significance (P =
0.07). While numbers of macrophages decreased with
EPO treatment at 14 days, numbers of microglia in-
creased significantly by almost six times relative to num-
bers in TAI + EPO rats at 7 days (201.30 ± 73.68 versus
34.27 ± 30.59, P <0.05).
Similar to TAI, TAI + Hx rats had an abundant
accumulation of both macrophages and microglia in
the corpus callosum at 7 days and 14 days postinjury
(Figure 9B). EPO treatment decreased numbers of mac-
rophages at 7 days when compared to vehicle-treated
TAI + Hx rats, although not significantly (14.24 ± 5.81
versus 38.70 ± 13.03, P = 0.08). At day 14, the number
of macrophages in TAI + Hx + EPO rats increased sig-
nificantly compared to day 7 (P <0.05). EPO treatment
caused a small, non-significant decrease in macrophages
when compared to TAI + Hx. In regard to the number of
microglia, a reduction of more than 60% was found in
TAI + Hx + EPO rats when compared to vehicle TAI +
Hx rats at 7 days, though this was not statistically sig-
nificant (6.58 ± 3.75 versus 15.66 ± 0.03, P = 0.42). Like-
wise, at 14 days, numbers of microglia in TAI +
Hx + EPO rats (50.17 ± 32.5) were substantially reduced
by 60% compared to vehicle TAI + Hx rats (122.10 ±
51.94, P = 0.38).
IL-1β is enhanced after TAI + Hx, and markedly
suppressed by erythropoietin
While IL-1β levels were elevated by 78% 2 hours after TAI
(Figure 10A), this increase was not significant relative to
sham control (3.935 ± 1.926 versus 0.5370 ± 0.20, P = 0.08).
After this time, TAI rats showed a steady decrease in IL-1β,
with a 48 hour concentration of 1.55 ± 0.55 pg/mg protein,
which although higher (0.87 ± 0.21 pg/mg protein) was not
statistically different to sham. Conversely, TAI +Hx rats
had a sharp significant increase in IL-1β levels at 2 hours
Figure 9 Accumulation of CD68-positive macrophages and microglia is reduced by erythropoietin (EPO) treatment after traumatic
axonal injury with hypoxia (TAI + Hx). In the corpus callosum CD68-positive (+ive) staining was classified on the basis of macrophage or
microglial appearance, with the number of each counted separately. (A) The ratio of macrophages to microglia demonstrated a shift between
7 and 14 d in TAI + EPO rats, with an early predominance of macrophages, followed by a more abundant accumulation of microglia at 14 d.
(B) The ratio of macrophages to microglia was similar at both 7 and 14 days in both TAI + Hx and TAI + Hx + EPO rats. Data expressed as
mean ± SEM, n = 6/group.
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relative to sham (11.47 ± 5.05 versus 0.87 ± 0.21 pg/mg pro-
tein, P <0.05; Figure 10B); which was an almost three-fold
increase when compared to TAI. Interestingly, the upregu-
lation of IL-1β in the white matter was substantially higher
compared to the concentration detected in the cortex of
TAI-Hx rats in our previously published study (3.10 ±
0.56 pg/mg protein) (Yan et al. 2011). IL-1β levels dropped
markedly from 2 hours to 24 hours (11.47 ± 5.05 versus
1.70 ± 0.68 pg/mg protein, P <0.05), with values returning
to sham values at both 24 and 48 hours postinjury.
When TAI rats were given EPO, a trend toward in-
crease in IL-1β levels was detected at 2 hours relative
to sham (P = 0.052), although interestingly, the level of
IL-1β was slightly (but not significantly) lower than
that observed for vehicle treated rats. At 24 hours,
IL-1β levels returned to sham values, and remained
similar until 48 hours. Comparison of IL-1β concentra-
tions between TAI and TAI + EPO groups showed no
statistical changes at any time point examined (2, 24, or
48 hours).
Conversely, in TAI + Hx rats, a single dose of EPO
given 1 hour after injury was sufficient to keep IL-1β
production to sham levels at 2 hours, with a dramatic
significant decrease from vehicle-treated TAI + Hx rats
of more than 90% (11.47 ± 5.05 versus 1.11 ± 0.34
pg/mg protein, P <0.05). Interestingly IL-1β levels
in TAI + Hx + EPO rats were significantly higher at
24 hours when compared to sham (3.83 ± 1.57 pg/mg
protein, P <0.05).
Discussion
In this study, we have demonstrated for the first time the
efficacy of EPO in reducing sensorimotor and cognitive
deficits, axonal and dendritic pathology, and the acute in-
flammatory response, concomitant to an increased expres-
sion of the endogenous EpoR in a combined rat model of
diffuse brain injury and post-traumatic hypoxia. Most im-
portantly, these benefits of EPO treatment did not occur
in animals subjected to TAI alone, suggesting that the
presence of hypoxia after injury has bolstered the neuro-
protective capacity of EPO, in a manner not seen in nor-
moxic conditions of TAI.
EPO has been shown to improve sensorimotor and
cognitive deficits in rats after both CCI and cryogenic le-
sion injuries [22-24,41], with a therapeutic window of
administration up to 24 h after injury reported to pro-
vide behavioural benefit [35]. In keeping with the litera-
ture, in our study the injection of EPO at 1 and 24 h
after TAI + Hx resulted in a sustained improvement in
the Rotarod. This test is an efficient measure of sensori-
motor impairment, which highlights fine changes in ves-
tibulomotor ability as well as prolonged deficits that may
be overlooked by less sensitive sensorimotor tests [36].
EPO-induced amelioration of motor function after
TAI + Hx on the Rotarod occurred from 5 days postin-
jury, with this beneficial effect maintained to 14 days.
While it is difficult to identify in a diffuse injury model
the precise area of the injured brain causing functional
deficit, and pinpoint the mechanism through which the
multifunctional EPO is able to provide benefit, there are
several possibilities. The most frequently posited hypoth-
esis attributes EPO-mediated neurological improvement
to a greater cerebral oxygenation and subsequent mitiga-
tion of metabolic dysfunction, as observed both clinically
and experimentally after ischemia and subarachnoid
haemorrhage [42-44]. However, a recent study by Meng
and colleagues reported that EPO’s therapeutic effects
occur independently of increased blood cell volume [35],
a finding also supported in the context of retinal
degeneration, in which tissue improvement was detected
without a concomitant increase in haematocrit [45]. Of
particular note is the finding that no beneficial effect of
EPO was observed in sensorimotor or cognitive tasks
when administered to TAI animals, indicating that the
Figure 10 The proinflammatory cytokine IL-1β is upregulated
acutely after traumatic axonal injury with hypoxia (TAI + Hx),
and its production is suppressed acutely by erythropoietin
(EPO). (A) IL-1β levels were elevated acutely above sham levels at 2 h
after TAI, with an increase approaching significance to sham in both TAI
and TAI + EPO groups. No statistical differences were found between
TAI and TAI + EPO groups at any time point examined (2, 24, or 48 h).
(B) TAI + Hx rats had a striking significant increase in IL-1β levels acutely
at 2 h when compared with sham. When TAI + Hx rats were treated
with a single dose of EPO 1 h after injury, IL-1β levels were suppressed
and remained at sham values, in contrast to saline-treated TAI + Hx rats.
Data expressed as mean ± SEM, n = 4/group. *P <0.05; 2-way ANOVA
with post-hoc Bonferroni test.
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benefit of EPO is intricately bolstered by hypoxia. In
support of this theory are the findings that EPO en-
hances neurological recovery in models of hypoxia-
ischemia, particularly with respect to sensorimotor and
spatial deficit [46-48], suggesting that hypoxia induction
is of critical importance in the potentiation of the
EPO-mediated response after brain insults. Further,
the oxygen sensing molecule hypoxia inducible factor
1 (HIF-1α) is stabilised only under hypoxic conditions by
binding to the EPO promoter to upregulate downstream
target genes including EPO and EPOR [49]. This sup-
ports an intimate relationship between hypoxia, EPO,
and expression of the EPO receptor and therapeutic
efficacy of EPO [50,51].
Many long-term behavioural consequences of TBI
have been attributed to circuit dysfunction as a result of
white matter damage and degeneration [52]. This degen-
eration may be exacerbated by hypoperfusion in an acute
and chronic setting, both experimentally [53-55] as well
as clinically, with studies reporting haemodynamic ab-
normalities and prolonged hypoperfusion up to 6 years
after TBI [56,57]. A key factor for cognitive recovery is
the improvement in white matter blood flow [56]; so it
may be speculated that EPO administration does ameli-
orate cerebral blood flow dysfunction, leading to an
overall improvement in a cognitive context. Here, we
have observed a significant atrophy of the corpus callo-
sum in TAI + Hx rats, with this pathology persisting to
7 days at which time we detected severe cognitive
dysfunction in the NORT. Interestingly, we found a
favourable effect of EPO in reversing the degradation of
the corpus callosum at each time point examined, and at
the same time, a significant improvement to sham levels
in the NORT, indicating that cognitive function may in-
deed be linked to white matter damage and degener-
ation. At the same time, we found that not only did EPO
significantly preserve the integrity of the corpus callo-
sum in TAI + Hx + EPO rats when compared to TAI +
Hx rats, but it also significantly enhanced the callosal
area when compared to sham treated rats.
Of particular interest for diffuse brain injury, we ob-
served a highly significant reduction in the number of
terminal axonal bulbs in the corpus callosum at 1 day
using the cytoskeletal protein marker NF-200 in TAI +
Hx + EPO rats when compared to TAI + Hx, indicating
that EPO was able to prevent progression of secondary
axonal pathology to a terminal state. Because EPO was
given at a first dose 1 hour after TAI + Hx and not prior
to injury, this reduction in axonal bulbs can be attrib-
uted only to EPO’s ability to mediate secondary patho-
logical events, with no effect on any potential immediate
shearing of axons. Interestingly, we also observed a de-
crease in the number of swollen axons present in the
corpus callosum at 1 day, and although this decrease
was not significant, perhaps due to variability observed
within groups, there was still a mean decrease of almost
three-fold when compared to TAI + Hx rats, indicating
that EPO was able to substantially reduce axonal swell-
ing by mediation of cytoskeletal degeneration/disruption,
potentially through attenuation of calpain-mediated
spectrin proteolysis, as has been shown when applied in
a hippocampal slice model of oxygen-glucose deprav-
ation [58]. At 7 days, TAI + Hx + EPO rats maintained a
lower number of both axonal bulbs and swollen axons,
indicating that EPO administration acutely at 1 and
24 hours after injury was sufficient not only to reduce
acute secondary events, but also to prevent progression
of pathology with a terminal end-point. These findings
were echoed in the pyramidal tracts of the brainstem,
and although we found that the reduction in number of
bulbs and swollen axons was not significant (again likely
due to intragroup variability) EPO apparently exerted a
beneficial effect in reducing pathological damage to the
axonal cytoskeleton in this region.
The microtubule-associated protein MAP2 is essential
for the function of the somatodendritic compartment of
neurons, and is the most abundant cytoskeletal protein
in the brain [59]. MAP2 has been shown to be particu-
larly vulnerable to brain injury, with a rapid loss of stain-
ing, which reveals significant dendritic pathology. In
focal injuries such as CCI, MAP2 loss is most prominent
in proximity to the lesion site [60] and is closely associ-
ated with cell death, whereas in FPI, its reduction is
regionally specific, with the hippocampus showing stron-
ger loss, and the cortex largely spared [61]. In this study,
we found a regional variation in MAP2 loss, with the
caudate putamen displaying most evident disruption.
Photomicrographs of this most damaged region after
TAI + Hx revealed patches devoid of MAP2 reactivity,
with densitometric analysis showing a decrease in dens-
ity to approximately half of that observed in sham rats.
Importantly, this alteration persisted until 14 days, indi-
cating that while cytoskeletal and transport dysfunction
in the axon have resolved, ongoing dendritic damage
may contribute to prolonged pathophysiology observed
after diffuse injury, and failure to recover from func-
tional deficits [61]. EPO administration to TAI + Hx rats
prevented injury-induced MAP2 loss as early as 1 d,
after a single injection of EPO given at 1 hour post-
injury. This beneficial effect of EPO was also maintained
at 7 and 14 days, with no differences detectable from
sham levels. The dendritic sparing afforded by EPO may
also contribute to behavioural improvement, with early
dendritic protection leading to an overall recovery in
functionality. Loss of MAP2 has been postulated to be
due to proteolytic degradation by Ca2+-dependent prote-
ases such as calpain, which, as mentioned, is also
thought to be a main perpetrator of spectrin damage in
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the axon. This finding of decreased MAP2 loss in con-
junction with reduced NF-200 positive staining indicates
that EPO’s beneficial effects on the neuron may be due
to a reduction in Ca2+ influx, and/or calpain-mediated
pathology. Interestingly, calpain also degrades the
membrane-bound EpoR, with this effect reversed by cal-
pain inhibition [62]. Therefore, EPO’s inhibition of cal-
pain activity might also exert effects on survival of the
EpoR, and thus positively modulate its ability to bind to
available EpoRs.
While there is a low constitutive expression of neur-
onal EpoR in the normal rodent brain [19,63,64], the
number of cells expressing EpoR has been shown to
increase dramatically in response to hypoxia/ischemia
clinically [65,66] and experimentally [67-71]. EpoR is
also rapidly upregulated in experimental stroke and glo-
bal ischemia [19,72,73] and focal TBI [74,75], although
upregulation of endogenous Epo/EpoR per se is not suf-
ficient for neuroprotection [76]. Increased expression of
EpoR does, however, provide a platform for exogenous
EPO treatment, which has also been shown to increase
EpoR expression further [76-78]. As the level of EpoR
expression is thought to mediate the neuroprotective ef-
fects of EPO [79], we were interested to determine
whether hypoxia alone, TAI, or the combination of both
insults would upregulate the expression of the EpoR,
and whether exogenous EPO administration would fur-
ther boost this expression. We demonstrated that the
highest expression of EpoR was in the pyramidal tracts
of the brainstem, and while we found a small, nonsignifi-
cant increase in the number of EpoR positive cells after
TAI or TAI + Hx at 1 day, EPO administration signifi-
cantly bolstered the number of cells staining positively
for the EpoR in TAI + Hx rats when compared to their
vehicle treated counterparts. In addition, EpoR levels
remained significantly high in these TAI + Hx + EPO rats
at 7 days, indicating a long-lasting stimulation of EpoR
expression by exogenous EPO.
Intriguingly, while we saw a beneficial effect of EPO in
boosting EpoR expression in the brainstem, we found no
benefit at all of EPO in the corpus callosum, with signifi-
cantly fewer EpoR positive cells present compared to the
brainstem. This finding is consistent with the signifi-
cantly heightened axonal pathology observed in the
brainstem, indicating that EPO may be most effective in
areas of robust tissue damage, with the highest expres-
sion of EpoR previously reported in brain infarct or le-
sion [80]. Additionally, in this study, we did not see an
increase in EpoR numbers in hypoxia only rats in either
region examined. Sanchez and colleagues [81] found a
1 hour hypoxic insult of 8% O2 was insufficient to stimu-
late upregulation of EpoR, but a significant effect was
achieved when treatment was repeated 3 times over an
extended period, indicating that while hypoxia in
combination with TAI was sufficient to stimulate EpoR
expression, isolated hypoxia may not be adequate.
We then employed immunofluorescence double label-
ling to determine the cell types staining positively for
EpoR. After TAI, expression of EpoR was present pre-
dominantly on neurons, with occasional co-localisation
with macrophages/microglia. EpoR did not co-localise
with astrocytes, or damaged axons. While EPO expres-
sion is restricted to neurons and astrocytes only, EpoR is
expressed on the cell membrane of neurons, astrocytes,
microglia, oligodendrocytes, and endothelial cells [82].
Previous reports have documented heightened expres-
sion of astrocytic EpoR under hypoxic conditions both
in vitro and in vivo [65,78,83], and thus, we hypothesised
increased numbers of astrocytes expressing the EpoR
after TAI + Hx, and even more so in TAI + Hx + EPO
rats, as EPO is thought to act in a paracrine manner in
the brain [83]; however, this was not corroborated. Con-
trary to a previous study [84] EpoR staining did not
co-localise with neurofilament staining. It is, however,
possible that any co-localisation may have been missed
using NF-200, as it shows only the most overt axonal
damage, whereas the use of light-chain NF may have de-
tected a larger number of axons. Because EpoR expres-
sion was observed predominantly in the injured white
matter and not on astrocytes or axons, it is possible that
EpoR is of an oligodendrocyte or endothelial, or vascular
cell origin.
Previously we have demonstrated an early elevation of
the cytokines IL-6, IL-1β, and TNF and macrophages/
microglia after TAI + Hx [10,15]. This coincided with an
increase in inflammatory cell numbers over time as
axonal damage subsides, in an effort to clear cellular
debris and promote repair [85,86]. However, macro-
phages and activated microglia also perpetuate second-
ary damage through the secretion of cytokines, free
radicals, and neurotoxic factors such as glutamate
[87-89]. Here, early upregulation of IL-1β in the white
matter of TAI + Hx rats indicates that IL-1β is produced
directly in the most injured tissues. IL-1β promotes
macrophage extravasation into damaged tissues [90], as
well as the production of other cytokines, prolonging the
inflammatory response [91]. Importantly, EPO adminis-
tration 1 hour after injury was sufficient to reduce IL-1β
to sham levels, highlighting EPO’s ability to modulate
neuroinflammation early and robustly after diffuse TBI,
as reported in models of focal brain injury [26-29]. Al-
though treatment with EPO was unable to reduce IL-1β
levels after TAI, there was notably less IL-1β production
in these rats. Following early reduction in IL-1β levels,
TAI + Hx + EPO rats had a concomitant decrease in the
number of infiltrating macrophages and microglia in the
corpus callosum at 7 days, and to a lesser extent at
14 days. Interestingly, the same finding did not apply in
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EPO-treated TAI rats; these rats had a significant in-
crease in macrophages compared to TAI alone at 7 days,
and a switch at 14 days to a predominance of microglia.
The high number of macrophages at 7 days in TAI +
EPO rats is out of proportion to the extent of axonal
damage, and particularly so when compared to TAI + Hx
rats, and it is possible that this inappropriate cellular im-
mune response at 7 days may be potentiating cerebral
inflammation, as evidenced by the high number of
microglia at 14 days. This finding has implications for
reparative mechanisms and neurological recovery, and
certainly requires further investigation to ascertain the
mechanisms by which EPO promotes inflammatory cell
infiltration/activation after TAI, but not TAI + Hx.
Conclusions
In this study, we have demonstrated that administration
of EPO to rats subjected to the combination of TAI and
hypoxia markedly improved behavioural and cognitive
performance, attenuated white matter damage, striking
resolution of neuronal damage spanning from the axon
to the dendrite, and suppressed the neuroinflammatory
response, with these results coinciding with enhanced
expression of EPO’s cognate receptor EpoR. Fascinat-
ingly, many of these changes occurred after a single in-
jection of EPO, providing compelling evidence of EPO’s
ability as a neuroprotective agent. Interestingly, few ben-
efits were observed when EPO was administered to TAI
rats without hypoxia, indicating that EPO’s neuroprotec-
tive capacity is bolstered under hypoxic conditions,
which may be an important consideration when EPO is
employed for neuroprotection in the clinic.
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